. . "Large intervention statin trials, comparing moderate and aggressive LDL-cholesterol lowering, have proved the hypothesis ?lower LDL-cholesterol is better?. This led to more ambitious target LDL-cholesterol levels < 2 mmol/L in patients with the presence of cardiovascular disease (CVD). This will lead to the changes in the strategy of hypolipidemic therapy. The basis of hypolipidemic therapy should be statins, including in subjects with the presence of diabetes mellitus or metabolic syndrome, as we have most evidence for them from intervention studies. The dose of the statin is necessary to adjust to the starting level of LDL-cholesterol to reach LDL-cholesterol goal level for appropriate category of risk. When it is not possible for very high starting levels, it is advised to decrease LDL-cholesterol levels at least for 40-50%. In patients with diabetes mellitus, metabolic syndrome and with hypertriglyceridemia, the secondary target of non-HDL-cholesterol or apolipoprotein B is recommended ("@en . "1"^^ . . . "Velk\u00E9 interven\u010Dn\u00ED studie se statiny, porovn\u00E1vaj\u00EDc\u00ED \u00FA\u010Dinky m\u00EDrn\u00E9ho a agresivn\u00EDho sn\u00ED\u017Een\u00ED LDL-cholesterolu (LDL-Ch), potvrzuj\u00ED hypot\u00E9zu %22ni\u017E\u0161\u00ED LDL-Ch je lep\u0161\u00ED%22 a vedou k dal\u0161\u00EDmu zp\u0159\u00EDsn\u011Bn\u00ED c\u00EDlov\u00FDch hodnot LDL-Ch pod 2,0 mmol/l u pacient\u016F s p\u0159\u00EDtomnost\u00ED kardiovaskul\u00E1rn\u00EDho onemocn\u011Bn\u00ED (KVO). Tato skute\u010Dnost povede i ke zm\u011Bn\u011B strategie hypolipidemick\u00E9 l\u00E9\u010Dby. Z\u00E1kladem hypolipidemick\u00E9 medikament\u00F3zn\u00ED l\u00E9\u010Dby by m\u011Bly b\u00FDt statiny, a to i u osob s p\u0159\u00EDtomnost\u00ED diabetu \u010Di metabolick\u00E9ho syndromu, nebo\u0165 pro n\u011B existuje nejv\u00EDce d\u016Fkaz\u016F z interven\u010Dn\u00EDch studi\u00ED. Druh a d\u00E1vku statinu je t\u0159eba volit mimo jin\u00E9 podle v\u00FDchoz\u00ED hodnoty lipid\u016F tak, aby bylo dosa\u017Eeno c\u00EDlov\u00E9 hodnoty LDL-Ch pro p\u0159\u00EDslu\u0161nou kategorii rizika. Nen\u00ED-li to mo\u017En\u00E9 pro p\u0159\u00EDli\u0161 vysok\u00E9 vstupn\u00ED hodnoty, je vhodn\u00E9 sn\u00ED\u017Een\u00ED LDL-Ch alespo\u0148 o 40 a\u017E 50%. U osob s diabetes mellitus, s metabolick\u00FDm syndromem a s hypetrigly cerid\u00E9mi\u00ED je doporu\u010Dov\u00E1na sekund\u00E1rn\u00ED c\u00EDlov\u00E1 hodnota non-HDL-Ch, event. apolipoproteinu B (<0,9 g/l u osob bez p\u0159\u00EDtomnosti KVO, <0,8 g/l u"@cs . . "RIV/61989592:15110/07:00004297!RIV08-MSM-15110___" . "Co nov\u00E9ho v medikament\u00F3zn\u00ED hypolipidemick\u00E9 l\u00E9\u010Db\u011B?"@cs . "What is new in the hypolipidemic therapy?"@en . "937-943" . . "What is new in the hypolipidemic therapy?"@en . . . "dyslipidemia; cardiovascular disease; statin; fibrate; nicotinic acid; ezetimibe; rimonabant; combination therapy"@en . "15110" . "Co nov\u00E9ho v medikament\u00F3zn\u00ED hypolipidemick\u00E9 l\u00E9\u010Db\u011B?" . "Co nov\u00E9ho v medikament\u00F3zn\u00ED hypolipidemick\u00E9 l\u00E9\u010Db\u011B?"@cs . . "RIV/61989592:15110/07:00004297" . . "Co nov\u00E9ho v medikament\u00F3zn\u00ED hypolipidemick\u00E9 l\u00E9\u010Db\u011B?" . . . "[CE481D959D90]" . "414004" . . "Velk\u00E9 interven\u010Dn\u00ED studie se statiny, porovn\u00E1vaj\u00EDc\u00ED \u00FA\u010Dinky m\u00EDrn\u00E9ho a agresivn\u00EDho sn\u00ED\u017Een\u00ED LDL-cholesterolu (LDL-Ch), potvrzuj\u00ED hypot\u00E9zu %22ni\u017E\u0161\u00ED LDL-Ch je lep\u0161\u00ED%22 a vedou k dal\u0161\u00EDmu zp\u0159\u00EDsn\u011Bn\u00ED c\u00EDlov\u00FDch hodnot LDL-Ch pod 2,0 mmol/l u pacient\u016F s p\u0159\u00EDtomnost\u00ED kardiovaskul\u00E1rn\u00EDho onemocn\u011Bn\u00ED (KVO). Tato skute\u010Dnost povede i ke zm\u011Bn\u011B strategie hypolipidemick\u00E9 l\u00E9\u010Dby. Z\u00E1kladem hypolipidemick\u00E9 medikament\u00F3zn\u00ED l\u00E9\u010Dby by m\u011Bly b\u00FDt statiny, a to i u osob s p\u0159\u00EDtomnost\u00ED diabetu \u010Di metabolick\u00E9ho syndromu, nebo\u0165 pro n\u011B existuje nejv\u00EDce d\u016Fkaz\u016F z interven\u010Dn\u00EDch studi\u00ED. Druh a d\u00E1vku statinu je t\u0159eba volit mimo jin\u00E9 podle v\u00FDchoz\u00ED hodnoty lipid\u016F tak, aby bylo dosa\u017Eeno c\u00EDlov\u00E9 hodnoty LDL-Ch pro p\u0159\u00EDslu\u0161nou kategorii rizika. Nen\u00ED-li to mo\u017En\u00E9 pro p\u0159\u00EDli\u0161 vysok\u00E9 vstupn\u00ED hodnoty, je vhodn\u00E9 sn\u00ED\u017Een\u00ED LDL-Ch alespo\u0148 o 40 a\u017E 50%. U osob s diabetes mellitus, s metabolick\u00FDm syndromem a s hypetrigly cerid\u00E9mi\u00ED je doporu\u010Dov\u00E1na sekund\u00E1rn\u00ED c\u00EDlov\u00E1 hodnota non-HDL-Ch, event. apolipoproteinu B (<0,9 g/l u osob bez p\u0159\u00EDtomnosti KVO, <0,8 g/l u" . "Postgradu\u00E1ln\u00ED medic\u00EDna" . . . "4" . . . . "9" . "7"^^ . "S" . "CZ - \u010Cesk\u00E1 republika" . "Vaverkov\u00E1, Helena" . "1"^^ . . "1212-4184" .